Abstract
Visual improvement following octreotide for growth hormone secreting pituitary macroadenomas is uncommon without tumour shrinkage. A 45-year old lady presented with blurred vision for 12 months. Visual assessment revealed a bitemporal hemianopia and CT scan demonstrated a large pituitary tumour with lateral and suprasellar extension. Acromegaly was confirmed by 75 g glucose tolerance testing. Primary transsphenoidal surgery was performed with normalisation of visual acuity and fields of vision. Post-operatively she had anterior pituitary hormone deficiency. As GH and IGF-1 levels remained elevated she underwent external pituitary irradiation. CT scanning demonstrated tumour shrinkage associated with a modest fall in GH levels. IGF-1 levels remained elevated falling to the age-related upper limit of normal after 5 years. At regular review she had stable visual acuity and fields of vision.
She presented as an emergency 7 years from presentation with reduced vision and recurrence of bitemporal hemianopia. An MRI demonstrated a large pituitary adenoma. We therefore undertook a carefully monitored trial of octreotide with great caution with daily reassessment of acuity and fields. A decision was made to proceed to surgery in the event of deterioration or lack of improvement after a short trial over 5–7 days. We observed normalisation of visual acuity and perimetry within 3 days. She then commenced long-acting octreotide (Sandostatin LAR) 20 mg every 28 days. MRI after 1 week showed shrinkage of the tumour by a few millimetres. Five months later repeat MRI failed to show any further improvement in tumour size. However she remains well 29 months from treatment with normal vision and is being monitored carefully as her chosen form of therapy.
Somatostatin analogues may be effective as therapy in a selected group of patients with acromegaly and visual loss who are not suitable for pituitary surgery. If used in this way the drug must be given cautiously with frequent detailed ongoing visual assessments. In this present case there has been a restoration of vision but the long-term outlook remains guarded without significant tumor shrinkage.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J, Giustina A. Guidelines for acromegaly management. J Clin Endocrinol Metab 2002;87:4054–4058.
Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB, Wass JA. Outcome of transsphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf) 1998;50:561–567.
Biermasz NR, Dulken H, Roelfsema F. Long-term followup results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab 2000;85:2476–2477.
Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM. Primary medical therapy for acromegaly: An open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulinlike growth factor-I, and tumor size. J Clin Endocrinol Metab 2002;87:4554–4563.
James RA, Chatterjee S, White MC, Hall K, Moller N, Kendall-Taylor P. Continuous infusion of octreotide in acromegaly. Lancet 1989;2:1083–1087.
Lundin P, Eden Engstrom B, Karlsson FA, Burman P. Longterm octreotide therapy in growth hormone-secreting pituitary adenomas: Evaluation with serial MR. Am J Neuroradiol 1997;18:765–772.
Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3034–3040.
Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001;86:2779–2786.
Cobb WE, Jackson I. Short-term recovery of visual field loss in acromegaly during treatment with a long-acting somatostatin analogue. The American Journal of Medicine 1999;86:496–497.
Broson-Chazot F, Houzard C, Ajzenberg C, Nocaudie M, Duet M, Mundler O, Marchandise X, Epelbaum J, Gomez De Alzaga M, Schafer J, Meyerhof W, Sassolas G, Warnet A. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: Correlation with hormonal and visual responses to octreotide. Clinical Endocrinology 1997;47:589–598.
Shimon I, Nass D, Hadani M. Acromegaly with normal growth hormone levels: Response to Sandostatin-LAR treatment. Pituitary 2000;2:289–294.
Jaffrain-Rea ML, Minniti G, Santoro A, Bastianello S, Tamburrano G, Gulino A, Cantore G. Visual improvement during octreotide therapy in a case of episellar meningioma. Clinical Neurology Neurosurgery 1998;100:40–43.
Lamberts SW, Van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. New England Journal Medicine 1996;25:46–54.
Philippon J, Foncin JF, Grob R, Srour A, Poisson M, Pertuiset BF. Cerebral edema associated with meningiomas: Possible role of a secretory-excretory phenomenon. Neurosurgery 1984;14:295–301.
Ducati A, Losa M, Fava E, Cenzato M, Giovanelli M. Acute effects on visual function of a Somatostatin analogue (SMS 201-995) evaluated using a neurophysiological approach. Journal of Endocrinological Investigation 1991;14(suppl 1, Abstract P144):120.
Mbanya JC, Mendelow AD, Crawford PJ, Hall K, Dewar JH, Kendall-Taylor P. Rapid resolution of visual abnormalities with medical therapy alone in patients with large prolactinomas. Br J Neurosurgery 1993;7:519–527.
Lesser RL, Zheutlin JD, Boghen D, Odel JG, Robbins RJ. Visual function improvement in patients with macroprolactinomas treated with bromocriptine. Am J Ophthalmology 1990;109:535–543.
Sieck JO, Niles NL, Jinkins JR, Al-Mefty O, el-Akkad S, Woodhouse N. Extrasellar prolactinomas: Successful management of 24 patients using bromocriptine. Hormone Research 1986;23:167–176.
Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 1997;82:3574–3579.
Wasko R, Ruchala M, Sawicka J, Kotwicka M, Liebert W, Sowinski J. Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly. Journal of Endocrinological Investigation 2000;23:12–18.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lindsay, J.R., Harding, J.A., Ellis, P.K. et al. Sustained Improvement in Vision in a Recurrent Growth Hormone Secreting Macroadenoma During Treatment with Octreotide in the Absence of Marked Tumour Shrinkage. Pituitary 6, 209–214 (2003). https://doi.org/10.1023/B:PITU.0000023433.21472.ab
Issue Date:
DOI: https://doi.org/10.1023/B:PITU.0000023433.21472.ab